Recursion Pharmaceuticals Balance Sheet
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Recursion Pharmaceuticals financial position
At the end of fiscal 2025, Recursion Pharmaceuticals reported total assets of $1.47 billion, up 1.8% from a year earlier against total liabilities of $343.3 million. Shareholders' equity stood at $1.13 billion, or 76.7% of assets. The company held $743.3 million in cash and equivalents against $18.7 million of debt, a net cash position of $724.6 million.
The current ratio (current assets divided by current liabilities) was 5.50, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.02.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 743.29M | 594.35M | 391.56M | 549.91M | 285.12M | 262.13M | 75.17M |
| Short-Term Investments | — | — | — | 0 | 231.45M | 0 | — |
| Receivables | — | — | — | 0 | 34.00K | 156.00K | — |
| Total Current Assets | 812.85M | 714.27M | 438.14M | 569.81M | 534.72M | 266.44M | — |
| Property, Plant & Equipment | 103.93M | 141.06M | 86.51M | 88.19M | 64.72M | 25.97M | — |
| Goodwill | 162.16M | 148.87M | 52.06M | 801.00K | 801.00K | 801.00K | — |
| Intangible Assets | 309.90M | 335.86M | 36.44M | 1.31M | 1.39M | 1.69M | — |
| Total Assets | 1.47B | 1.45B | 653.70M | 701.29M | 610.35M | 298.58M | — |
| Accounts Payable | 18.12M | 21.61M | 3.95M | 4.59M | 2.82M | 1.07M | — |
| Short-Term Debt | 9.09M | 8.43M | 41.00K | — | — | — | — |
| Total Current Liabilities | 147.71M | 187.47M | 93.17M | 100.27M | 46.66M | 23.10M | — |
| Long-Term Debt | 9.56M | 19.02M | 1.10M | 536.00K | 633.00K | 11.41M | — |
| Total Liabilities | 343.26M | 413.82M | 190.26M | 215.48M | 67.41M | 56.56M | — |
| Shareholders' Equity | 1.13B | 1.03B | 463.44M | 485.81M | 542.94M | -206.29M | -124.27M |
| Retained Earnings | -2.08B | -1.43B | -967.62M | -639.56M | -400.08M | -213.60M | — |
| Total Debt | 18.66M | 27.45M | 1.14M | 536.00K | 633.00K | 11.41M | — |
| Net Cash (Debt) | 724.64M | 566.90M | 390.42M | 549.38M | 515.93M | 250.71M | 75.17M |
| Shares Outstanding | 528.18M | 396.80M | 234.27M | 191.02M | 170.27M | 22.31M | — |
This table shows 7 annual periods of Recursion Pharmaceuticals's balance sheet, from FY 2025 back to FY 2019, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RXRX's reporting calendar. What is a balance sheet?